Chapter 17: Common and Preferred Stock Financing
EPS after rights offering = Net income/(Old + New shares)
f. No, he would expect greater earnings. He and others have put
additional capital into the corporation so total claims to earnings
COMPREHENSIVE PROBLEM
Comprehensive Problem 2.
Electro Cardio Systems Inc. (poison pill strategy) (LO17-4) Dr. Robert Grossman founded
Electro Cardio Systems Inc. (ECS) in 2001. The principal purpose of the firm was to engage in
the research and development of heart pump devices. Although the firm did not show a profit
until 2006, by 2010 it reported aftertax earnings of $1,200,000. The company had gone public in
2004 at $10 a share. Investors were initially interested in buying the stock because of its future
prospects. By year-end 2010, the stock was trading at $42 per share because the firm had made
good on its promise to produce lifesaving heart pumps and, in the process, was now making
reasonable earnings. With 850,000 shares outstanding, earnings per share were $1.41.
Dr. Grossman and the members of the board of directors were initially pleased when another
firm, Parker Medical Products, began buying their stock. John Parker, the chairman and CEO of
Parker Medical Products, was thought to be a shrewd investor and his company’s purchase of
50,000 shares of ECS was taken as an affirmation of the success of the firm.
However, when Parker bought another 50,000 shares, Dr. Grossman and members of the
board of directors of ECS became concerned that John Parker and his firm might be trying to take
over ECS.
Upon talking to her attorney, Dr. Grossman was reminded that ECS had a poison pill
provision that took effect when any outside investor accumulated 25 percent or more of the shares
outstanding. Current stockholders, excluding the potential takeover company, were given the
privilege of buying up to 500,000 shares of ECS at 80 percent of current market value. Thus new
shares would be restricted to friendly interests.
Copyright © 2017 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent
of McGraw-Hill Education.